Investing in French Biotech--When It's Not Too French

Neuro 3d's €31.5 million third round late in 2004 was one of France's largest private biotech financings for years. But none of the investors are looking to France to provide the exit opportunities, which are more likely to be found in M&A, or in Switzerland.

The French government has always been vocal about its desire to turn France into a leader in innovation and high tech industries. On the pharma side, it certainly influenced heavily the success of Sanofi-Synthélabo's acquisition of Aventis to create Sanofi-Aventis —now the top European drug firm, with headquarters firmly established in Paris. [See Deal] (See "Can Political M&A Make Commercial Sense?" In Vivo Europe Rx, June 2004Also see "Can Political M&A Make Commercial Sense?" - In Vivo, 1 June, 2004..) The country's biotech industry has manifestly failed to take off, however, despite a top quality research base. Not a single company has floated since 1999, half a dozen have tried but failed over the period. Only six firms are listed—and those such as Flamel Technologies SA with dual listings are traded most actively in the US. The entrepreneurial spirit, drawn out of its socialist den during the 1997-2000 boom, has largely retreated along with most VC funding and public investors.

Hence CNS group Neuro3d SA 's €31.5 million ($42.7 million) third round financing in December 2004 provided welcome good...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.